Elite in Acute Myeloid Leukemia (AML)

Dr. Gautam M. Borthakur

University of Texas System

University Of Texas MD Anderson Cancer Center

Houston, TX

Elite

in Acute Myeloid Leukemia (AML)

Specialties:Hematology Oncology

Experience:39 Years

Clinical Trials:Currently Recruiting for 10 Trials

Accepts:New PatientsMedicare

About|Expertise|Insurance|Location|Research

Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Elite

Distinguished

Advanced

View 41 More Conditions +

Check Dr. Gautam M. Borthakur's experience treating your condition:

About Dr. Gautam M. Borthakur

Gautam Borthakur is a Hematologist Oncology expert in Houston, Texas. Borthakur has been practicing medicine for over 39 years and is rated as an Elite expert by MediFind in the treatment of Acute Myeloid Leukemia (AML). He is also highly rated in 36 other conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration. He is licensed to treat patients in Texas. Borthakur is currently accepting new patients.

His clinical research consists of co-authoring 430 peer reviewed articles and participating in 29 clinical trials in the past 15 years. In particular, he has co-authored 273 articles and participated in 16 clinical trials in the study of Acute Myeloid Leukemia (AML).

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Gautam M. Borthakur it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Call to see if your plan is accepted.

Locations

1515 Holcombe Blvd, 30 Unit Number 4, Houston, TX 77030

713-792-XXXX

Background & Education

Graduate Institution

Other, 1984

Specialties

Hematology Oncology

Licenses

Internal Medicine in TX

Hospital Affiliations

University Of Texas MD Anderson Cancer Center

Languages Spoken

English

Gender

Male

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

29 Clinical Trials

A Phase Ib Study of RVU120 (SEL120) in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome

Enrollment Status: Recruiting

Publish Date: December 12, 2022

Intervention Type: Drug

Study Drug: RVU120

Study Phase: Phase 1

Tamibarotene in Combination With Venetoclax and Azacitidine in Adult Patients With RARA-positive, Previously Untreated AML Who Are Ineligible for Standard Induction Therapy

Enrollment Status: Recruiting

Publish Date: December 09, 2022

Intervention Type: Drug

Study Drugs: TamibaroteneVenetoclaxAzacitidine

Study Phase: Phase 2

Phase I/II Study of Oral ONC201 in Patients With Relapsed or Refractory Acute Leukemias and High-Risk Myelodysplastic Syndromes

Enrollment Status: Recruiting

Publish Date: September 23, 2022

Intervention Type: Drug

Study Drugs: ONC201Cytarabine

Study Phase: Phase 1/Phase 2

A Phase 2 Study of Fludarabine, Cytarabine, Filgrastim-sndz,Gemtuzumab Ozogamicin and Idarubicin in Newly Diagnosed Core Binding Factor Associated Acute Myelogenous Leukemia

Enrollment Status: Recruiting

Publish Date: July 28, 2022

Intervention Type: Drug, Other, Biological

Study Drugs: CytarabineDecitabineFilgrastimFludarabineGemtuzumabIdarubicin

Study Phase: Phase 2

Phase 1b/2 Clinical Study of the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of CFI-400945 as a Single Agent or in Combination With Azacitidine or Decitabine in Patients With AML, MDS or CMML

Enrollment Status: Recruiting

Publish Date: July 21, 2022

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

A Phase I Pharmacologic Study of CYC140, a Polo-like Kinase 1 Inhibitor, in Patients With Advanced Leukemias or Myelodysplastic Syndromes

Enrollment Status: Recruiting

Publish Date: April 25, 2022

Intervention Type: Drug

Study Drug: CYC140

Study Phase: Phase 1

A Phase 1 Trial to Investigate the Safety, Pharmacokinetic Profiles and the Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

Enrollment Status: Recruiting

Publish Date: April 20, 2022

Intervention Type: Drug

Study Drug: Tinostamustine

Study Phase: Phase 1

A Phase 1 Study of NKX101, an Activating Chimeric Receptor Natural Killer Cell Therapy, in Subjects With Hematological Malignancies or Dysplasias

Enrollment Status: Recruiting

Publish Date: April 15, 2022

Intervention Type: Biological

Study Drug: Allogeneic NKG2D-Targeted CAR-Natural Killer T Cells

Study Phase: Phase 1

A Phase 1/2, Open Label, Multicenter Study to Investigate the Safety and Efficacy of Fadraciclib (CYC065), an Oral CDK 2/9 Inhibitor, in Subjects With Leukemias or Myelodysplastic Syndrome (MDS)

Enrollment Status: Recruiting

Publish Date: April 04, 2022

Intervention Type: Drug

Study Drug: Fadraciclib

Study Phase: Phase 1/Phase 2

Phase 1B Open-Label, Dose-Escalation and Dose-Expansion Study of APVO436 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High-Grade Myelodysplastic Syndrome (MDS)

Enrollment Status: Recruiting

Publish Date: February 10, 2022

Intervention Type: Biological

Study Drug: APVO436

Study Phase: Phase 1

An Open-Label, Phase 2 Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed/Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplastic Syndrome

Enrollment Status: Completed

Publish Date: November 23, 2022

Intervention Type: Biological

Study Drug: Daratumumab

Study Phase: Phase 2

A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma

Enrollment Status: Terminated

Publish Date: November 15, 2022

Intervention Type: Drug

Study Drugs: BL-8040 CD34-Positive Hematopoietic CellsNelarabine

Study Phase: Phase 2

Phase 1 A/B Study of LY2606368 in Combination With Cytarabine and Fludarabine in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HRMDS)

Enrollment Status: Completed

Publish Date: September 02, 2022

Intervention Type: Drug, Other

Study Drugs: CytarabineFludarabine PhosphatePrexasertib

Study Phase: Phase 1

A Phase I Combination Study of CYC065 and Venetoclax in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes

Enrollment Status: Active, not recruiting

Publish Date: April 25, 2022

Intervention Type: Drug

Study Drugs: CYC065Venetoclax

Study Phase: Phase 1

A Phase I/II Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents in Participants With Myelodysplastic Syndrome and Acute Myeloid Leukaemia

Enrollment Status: Terminated

Publish Date: February 28, 2022

Intervention Type: Drug

Study Drugs: GSK33265955-Azacitidine

Study Phase: Phase 1

Eltrombopag for the Management of Thrombocytopenia Associated With Tyrosine Kinase Therapy in Patients With Chronic Myeloid Leukemia (CML) and Myelofibrosis (MF)

Enrollment Status: Completed

Publish Date: January 20, 2022

Intervention Type: Drug

Study Drug: Eltrombopag Olamine

Study Phase: Phase 2/Phase 3

A Phase I/II Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies

Enrollment Status: Completed

Publish Date: May 19, 2021

Intervention Type: Drug

Study Phase: Phase 2

A Phase 1b/Randomized Phase 2 Study to Evaluate LY3039478 in Combination With Dexamethasone in T-ALL/T-LBL Patients

Enrollment Status: Completed

Publish Date: September 11, 2019

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

An Open-label Phase 2 Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed/Refractory B-cell or T-cell Precursor Acute Lymphoblastic Leukemia (ALL)

Enrollment Status: Withdrawn

Publish Date: July 26, 2018

Intervention Type: Drug

Study Phase: Phase 2

A Phase 2 Study of E7070, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-risk Myelodysplastic Syndromes

Enrollment Status: Completed

Publish Date: July 03, 2018

Intervention Type: Drug

Study Phase: Phase 2

A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination With 5-azacitidine in Subjects With Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-azacitidine Therapy

Enrollment Status: Completed

Publish Date: April 21, 2016

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

Phase II Study of Methotrexate, Vincristine, Pegylated L-asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage

Enrollment Status: Completed

Publish Date: June 29, 2015

Intervention Type: Drug

Study Phase: Phase 2

Phase II Study of Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome

Enrollment Status: Completed

Publish Date: September 13, 2013

Intervention Type: Drug

Study Phase: Phase 2

Phase II Study of Lenalidomide in Patients With Relapsed/Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplastic Syndrome Associated With Chromosome 5 Abnormalities

Enrollment Status: Completed

Publish Date: August 14, 2013

Intervention Type: Drug

Study Phase: Phase 2

Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS

Enrollment Status: Completed

Publish Date: August 07, 2012

Intervention Type: Drug

Study Phase: Phase 2

Phase II Study of Lenalidomide and Darbepoetin Alfa in Myelodysplastic Syndrome (Low to Intermediate-1 Risk Category Excluding 5q Deletion)

Enrollment Status: Terminated

Publish Date: August 07, 2012

Intervention Type: Drug

Study Phase: Phase 2

A Phase I-II Study of Oxaliplatin, Fludarabine, and Cytarabine in Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes at First Relapse With Complete Remission Duration < 1 Year

Enrollment Status: Terminated

Publish Date: August 07, 2012

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

A Phase I Open-Label Study of S-Trans, Trans-Farnesylthiosalicylic Acid (FTS) Administered on Days 1 to 21 of a 28 Day Cycle in Patients With Advanced Hematologic Malignancies

Enrollment Status: Completed

Publish Date: August 01, 2012

Intervention Type: Drug

Study Phase: Phase 1

Phase 2 Study of NOV-002 in Low and Intermediate-1 Risk Myelodysplastic Syndrome

Enrollment Status: Withdrawn

Publish Date: July 30, 2012

Intervention Type: Drug

Study Phase: Phase 2

View 19 Less Clinical Trials -

431 Total Publications

AML-325 Prognostic Impact of RAS and C-KIT Mutations (Single vs. Multiple) in Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) Treated With a Fludarabine, Cytarabine, and G-CSF (FLAG)- Based Regimen.

Journal: Clinical lymphoma, myeloma & leukemia

Published: September 27, 2022

View All 431 Publications

Save this doctor for later

Looking for the best doctor for you?

Start Here

Is this your doctor?

Find a second opinion

Not sure about your diagnosis?

Check Your Symptoms

Learn about our expert tiers

Learn more

Similar Doctors

Dr. Naval G. Daver

Hematology Oncology | Oncology

Elite

Highly rated in

conditions

Hematology Oncology
Oncology

University of Texas System

University Of Texas MD Anderson Cancer Center

1515 Holcombe Blvd,

Houston, TX

Naval Daver is a Hematologist Oncology specialist and an Oncologist in Houston, Texas. Daver has been practicing medicine for over 19 years and is rated as an Elite expert by MediFind in the treatment of Acute Myeloid Leukemia (AML). He is also highly rated in 41 other conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration. He is licensed to treat patients in Texas. Daver is currently accepting new patients.

Dr. Courtney D. Dinardo

Hematology Oncology

Elite

Highly rated in

conditions

Hematology Oncology

University of Texas System

Physicians Referral Service

1515 Holcombe Blvd,

Houston, TX

Courtney Dinardo is a Hematologist Oncology expert in Houston, Texas. Dinardo has been practicing medicine for over 17 years and is rated as an Elite expert by MediFind in the treatment of Acute Myeloid Leukemia (AML). She is also highly rated in 36 other conditions, according to our data. Her top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration. She is licensed to treat patients in Texas and Pennsylvania. Dinardo is currently accepting new patients.

Dr. Hagop M. Kantarjian

Hematology Oncology | Oncology | Hematology

Elite

Highly rated in

conditions

Hematology Oncology
Oncology
Hematology

University of Texas System

Physicians Referral Service

1515 Holcombe Blvd,

Houston, TX

Hagop Kantarjian is a Hematologist Oncology specialist and an Oncologist in Houston, Texas. Kantarjian has been practicing medicine for over 44 years and is rated as an Elite expert by MediFind in the treatment of Acute Myeloid Leukemia (AML). He is also highly rated in 59 other conditions, according to our data. His top areas of expertise are Chronic Myelogenous Leukemia (CML), Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Marrow Aspiration. He is licensed to treat patients in Texas. Kantarjian is currently accepting new patients.